How have AKTX shares performed in 2024?

Akari Therapeutics' stock was trading at $3.12 at the start of the year. Since then, AKTX stock has decreased by 61.2% and is now trading at $1.21. View the best growth stocks for 2024 here .

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,500 shares, an increase of 75.0% from the March 15th total of 6,000 shares. Based on an average trading volume of 11,900 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.2% of the shares of the stock are sold short. View Akari Therapeutics' Short Interest .

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our AKTX earnings forecast .

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) issued its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing the consensus estimate of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics shares reverse split before market open on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , TherapeuticsMD (TXMD) , Biocept (BIOC) , OPKO Health (OPK) , Anavex Life Sciences (AVXL) , Rigel Pharmaceuticals (RIGL) , Teva Pharmaceutical Industries (TEVA) , Vascular Biogenics (VBLT) and Heat Biologics (HTBX) .

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free AKTX Stock Alerts

$1.21

+0.09 (+8.04%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.11
▼
$1.23
50-Day Range: $1.16
▼
$2.50
52-Week Range: $1.08
▼
$5.50

Volume: 8,776 shs
Average Volume: 12,553 shs
Market Capitalization: $9.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines Ownership SEC Filings Short Interest Social Media

Get Akari Therapeutics alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Akari Therapeutics Stock (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AKTX Stock News Headlines

April 16, 2024 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.com

April 15, 2024 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 15, 2024 | globenewswire.com

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

April 12, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading

April 12, 2024 | msn.com

Dindin lethal in Akari’s disposal of Capital1

April 11, 2024 | americanbankingnews.com

Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 75.0% in March

April 1, 2024 | finance.yahoo.com

Akari Therapeutics Insider Ups Holding By 69% During Year

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 1, 2024 | globenewswire.com

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

March 17, 2024 | msn.com

PVL: Fifi Sharma, Ced Domingo power Akari romp of Nxled

March 7, 2024 | bizjournals.com

Petri Dish: C4’s deal with Merck KGaA; Boston and California biotechs merge

March 6, 2024 | stockhouse.com

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NS

March 5, 2024 | businesswire.com

AKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to Shareholders

February 27, 2024 | msn.com

PVL: Grethcel Soltones, Akari still a work in progress

February 25, 2024 | msn.com

PVL: Ced Domingo has a quiet Akari debut as she adjusts to new system

February 24, 2024 | msn.com

PVL: Cignal turns back Akari to open All-Filipino bid

February 16, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading

February 9, 2024 | msn.com

PVL: Akari’s Max Juangco taking pressure of her pro debut in stride

February 7, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Slightly Lower in Wednesday Trading

February 2, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week Higher

January 23, 2024 | investing.com

Akari Therapeutics PLC (AKTX)

January 22, 2024 | msn.com

PVL: Faith Nisperos, Akari Chargers aim for Final Four

January 2, 2024 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

January 2, 2024 | finance.yahoo.com

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

January 2, 2024 | finance.yahoo.com

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

December 16, 2023 | msn.com

Akari Therapeutics Plc - ADR (AKTX) Price Target Increased by 45.45% to 81.60

See More Headlines

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/31/2020
Today: 4/19/2024
Next Earnings (Estimated): 5/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AKTX
CUSIP: N/A
CIK: 1541157
Web: www.akaritx.com
Phone: 442080040261
Fax: 646-843-9352
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.95
Quick Ratio: 0.95

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.03) per share
Price / Book: -40.33

Miscellaneous

Outstanding Shares: 7,920,000
Free Float: 3,027,000
Market Cap: $9.58 million
Optionable: Not Optionable
Beta: 0.96

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Ms. Rachelle Suzanne Jacques (Age 53)
President, CEO & Director
Comp: $1.38M
Ms. Wendy F. DiCicco CPA (Age 57)
Interim Chief Financial Officer
Ms. Melissa Bradford-Klug (Age 54)
Chief Operating Officer
Dr. Miles Nunn (Age 55)
Chief Scientific Officer
Dr. John F. Neylan III (Age 71)
M.D., Executive VP & Chief Medical Officer
Ms. Beth-Anne Lang
Senior Vice President of Regulatory Affairs
Annie Mack
Financial Controller

Key Competitors

View All Competitors

Institutional Ownership

Omnia Family Wealth LLC
Bought 28,511 shares on 2/5/2024
Ownership: 1.551%

View All Institutional Transactions

AKTX Stock Analysis - Frequently Asked Questions

How have AKTX shares performed in 2024?: Akari Therapeutics' stock was trading at $3.12 at the start of the year. Since then, AKTX stock has decreased by 61.2% and is now trading at $1.21.
View the best growth stocks for 2024 here.
Are investors shorting Akari Therapeutics?: Akari Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,500 shares, an increase of 75.0% from the March 15th total of 6,000 shares. Based on an average trading volume of 11,900 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.2% of the shares of the stock are sold short.
View Akari Therapeutics' Short Interest.
When is Akari Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AKTX earnings forecast.
How were Akari Therapeutics' earnings last quarter?: Akari Therapeutics, Plc (NASDAQ:AKTX) issued its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing the consensus estimate of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?: Akari Therapeutics shares reverse split before market open on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Akari Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX).
How do I buy shares of Akari Therapeutics?: Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial